Skip to content

NDA (New Drug Application)

Last reviewed

A New Drug Application (NDA) is the application a sponsor submits to the US FDA for approval to market a new drug in the United States. It presents the evidence that the drug is safe and effective for its proposed use and that it can be manufactured to a consistent quality.

Key facts

Regulation21 CFR Part 314
FormatCTD structure, submitted as an eCTD
For biologicsBiologics License Application (BLA)
Broadly comparable in the EUMarketing Authorisation Application (MAA)

IND and NDA

An IND comes first and allows clinical trials to begin. The NDA comes after the pivotal trials and brings together the quality, nonclinical and clinical evidence gathered during development.

Sources

Read more